Ramos-Casals Manuel, Brito-Zerón Pilar, Cuadrado Maria-Jose, Khamashta Munther A
Servei de Malalties Autoimmunes, Hospital Clínic, C/Villarroel, 170, 08036-Barcelona, Spain.
Curr Rheumatol Rep. 2008 Dec;10(6):442-8. doi: 10.1007/s11926-008-0072-z.
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to these new therapeutic agents. We have analyzed the clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of vasculitis developed after TNF-targeted therapy. A total of 132 cases, identified up to July 2008, are included and analyzed in this review.
肿瘤坏死因子（TNF）靶向治疗越来越多地用于治疗数量迅速增加的风湿性和自身免疫性疾病。随着这种治疗方法的应用以及治疗随访期的延长，与这些新型治疗药物相关的自身免疫过程发展的报告越来越多。我们分析了在TNF靶向治疗后发生血管炎的所有报告中，与使用的不同抗TNF药物相关的临床特征、结局及关联模式。本综述纳入并分析了截至2008年7月确定的总共132例病例。
Zotero 插件